Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-response study of JNJ-54781532 in moderately to severely active ulcerative colitis
2013-000263-88Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of peficitinib in autoimmune colitis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in the Mayo score at Week 8. Started Oct 2013; status: completed.
02
Drugs
peficitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-000263-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000263-88.